Cited by 653Cancer-related Molecular PathwaysUbiquitin and proteasome pathwaysHeat shock proteins research

The DOI matches its Crossref record; 134 of the 144 references it cites were found in a registry or an index.

MDM2 — master regulator of the p53 tumor suppressor protein

Momand, Jamil, Wu, Hsiao-Huei, Dasgupta, Gargi·2000·Gene

Open this paper in CoChat — free account

Abstract

MDM2 is an oncogene that mainly functions to modulate p53 tumor suppressor activity. In normal cells the MDM2 protein binds to the p53 protein and maintains p53 at low levels by increasing its susceptibility to proteolysis by the 26S proteosome. Immediately after the application of cellular stress, the ability of MDM2 to bind to p53 is blocked or altered in a fashion that prevents MDM2-mediated degradation. As a result, p53 levels rise, causing cell cycle arrest or apoptosis. In this review, we present evidence for the existence of three highly conserved regions (CRs) shared by MDM2 proteins and MDMX proteins of different species. These highly conserved regions encompass residues 42-94 (CR1), 301-329 (CR2), and 444-483 (CR3) on human MDM2. These three domains are respectively important for binding p53, for binding the retinoblastoma protein, and for transferring ubiquitin to p53. This review discusses the major milestones uncovered in MDM2 research during the past 12 years and potential uses of this knowledge in the fight against cancer.

Integrity signals

Registry

Crossref · 10.1016/s0378-1119(99)00487-4

Cites

134 of 134 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

THE UBIQUITIN SYSTEM
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Self-citation

Show all 144 references

Sorted by citations

Surfing the p53 network
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Gamma knife radiosurgery for trigeminal neuralgia associated with multiple sclerosis
Rogers, L., Shetter, A. G., Ponce, F. A., Fiedler, J. A., Smith, K. A., & Speiser, B. L. (2002) · Journal of neurosurgery · doi:10.3171/jns.2002.97.supplement_5.0529 · Cited by 1,770
Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies
Pistritto, G., Trisciuoglio, D., Ceci, C., Garufi, A., & D’Orazi, G. (2016) · Aging · doi:10.18632/aging.100934 · Cited by 1,721
High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.
Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K. R., MacLeod, G., Mis, M., Zimmermann, M., Fradet-Turcotte, A., Sun, S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.015 · Cited by 1,571
The proteasome: a suitable antineoplastic target
Adams, J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1361 · Cited by 1,214
Promoting apoptosis as a strategy for cancer drug discovery
Fesik, S. W. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1736 · Cited by 1,104
Decision making by p53: life, death and cancer
Oren, M. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401183 · Cited by 1,085
Dynamics of the p53-Mdm2 feedback loop in individual cells
Lahav, G., Rosenfeld, N., Sigal, A., Geva‐Zatorsky, N., Levine, A. J., Elowitz, M. B., & Alon, U. (2004) · Nature Genetics · doi:10.1038/ng1293 · Cited by 1,026
HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation
Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-973 · Cited by 951
Regulation of p53 activity through lysine methylation
Chuikov, S., Kurash, J. K., Wilson, J. R., Xiao, B., Justin, N., Ivanov, G. S., McKinney, K. M., Tempst, P., Prives, C. L., Gamblin, S. J., et al. (2004) · Nature · doi:10.1038/nature03117 · Cited by 846
The p53–Mdm2 module and the ubiquitin system
Michael, D., & Oren, M. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00099-8 · Cited by 772
ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage
Maya, R., Balass, M., Kim, S.-T., Shkedy, D., Leal, J.-F. M., Shifman, O., Moas, M., Buschmann, T., Ronai, Z., Shiloh, Y., et al. (2001) · Genes & Development · doi:10.1101/gad.886901 · Cited by 731
“The positions of the main identified structural domains of the protein ( Momand et al. 2000 ) are also indicated.”
BackgroundInfluential
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
Strebhardt, K. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3184 · Cited by 657
Oscillations and variability in the p53 system
Geva‐Zatorsky, N., Rosenfeld, N., Itzkovitz, S., Milo, R., Sigal, A., Dekel, E., Yarnitzky, T., Liron, Y., Polak, P. P., Lahav, G., et al. (2006) · Molecular Systems Biology · doi:10.1038/msb4100068 · Cited by 658
Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
The molecular biology of cancer
Bertram, J. S. (2000) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(00)00007-8 · Cited by 610
Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53
Katayama, H. G., Sasai, K., Kawai, H., Yuan, Z.-M., Bondaruk, J. E., Suzuki, F., Fujii, S., Arlinghaus, R. B., Czerniak, B. A., & Sen, S. (2003) · Nature Genetics · doi:10.1038/ng1279 · Cited by 595
The role of p53 in cancer drug resistance and targeted chemotherapy
Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2016) · Oncotarget · doi:10.18632/oncotarget.13475 · Cited by 612
Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis
Gottlieb, T. M., Martínez-Leal, J. F., Seger, R., Taya, Y., & Oren, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205181 · Cited by 473
Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment
Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462
Genetic Susceptibility to Cancer
Dong, L. M., Potter, J. D., White, E., Ulrich, C. M., Cardon, L. R., & Peters, U. (2008) · JAMA · doi:10.1001/jama.299.20.2423 · Cited by 460
Regulating tumor suppressor genes: post-translational modifications
Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449
E3 ubiquitin ligases: styles, structures and functions
Yang, Q., Zhao, J., Chen, D., & Wang, Y. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00043-2 · Cited by 435
Structure–function–rescue: the diverse nature of common p53 cancer mutants
Joerger, A. C., & Fersht, A. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210291 · Cited by 442
p53-Dependent apoptosis pathways
Shen, Y., & White, E. (2001) · Advances in cancer research · doi:10.1016/s0065-230x(01)82002-9 · Cited by 424
The PTEN, Mdm2, p53 tumor suppressor–oncoprotein network
Mayo, L. D., & Donner, D. B. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(02)02166-7 · Cited by 419
Targeting cell cycle regulation in cancer therapy
Díaz‐Moralli, S., Tarrado‐Castellarnau, M., Miranda, A., & Cascante, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.011 · Cited by 372
SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression
Wang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barrière, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0799 · Cited by 328
Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment
Kumar, A., Ma, H., Zhang, X., Huang, K., Jin, S., Liu, J., Wei, T., Cao, W., Zou, G., & Liang, X. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.058 · Cited by 315
Amplification of Mdmx (or Mdm4 ) Directly Contributes to Tumor Formation by Inhibiting p53 Tumor Suppressor Activity
Danovi, D., Meulmeester, E., Pasini, D., Migliorini, D., Capra, M., Frenk, R., de Graaf, P., Francoz, S., Gasparini, P., Gobbi, A., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5835-5843.2004 · Cited by 310
MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting
Bond, G. L., Hu, W., & Levine, A. J. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332627 · Cited by 310
p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products
Yin, Y., Stephen, C. W., Luciani, M. G., & Fåhræus, R. (2002) · Nature Cell Biology · doi:10.1038/ncb801 · Cited by 305
p53: Protection against Tumor Growth beyond Effects on Cell Cycle and Apoptosis
Wang, X., Simpson, E. R., & Brown, K. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0563 · Cited by 309
Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
Wang, S., Zhao, Y., Aguilar, A., Bernard, D., & Yang, C.-Y. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026245 · Cited by 300
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53
Sur, S., Pagliarini, R. A., Bunz, F., Rago, C., Diaz, L. A., Kinzler, K. W., Vogelstein, B., & Papadopoulos, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813333106 · Cited by 293
Stabilization of Mdm2 via Decreased Ubiquitination Is Mediated by Protein Kinase B/Akt-dependent Phosphorylation
Feng, J., Tamaskovic, R., Yang, Z., Brazil, D. P., Merlo, A., Hess, D., & Hemmings, B. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404936200 · Cited by 294
Nucleophosmin (B23) Targets ARF to Nucleoli and Inhibits Its Function
Korgaonkar, C. K., Hagen, J., Tompkins, V. S., Frazier, A. A., Allamargot, C., Quelle, F. W., & Quelle, D. E. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.4.1258-1271.2005 · Cited by 294
The p53 and Mdm2 families in cancer
Michael, D. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00264-7 · Cited by 288
Posttranslational modification of MDM2.
Meek, D. W., & Knippschild, U. (2003) · PubMed · Cited by 280
Control of the G2/M Transition
Stark, G. R., & Taylor, W. R. (2006) · Molecular Biotechnology · doi:10.1385/mb:32:3:227 · Cited by 282
The roles of nucleolin subcellular localization in cancer
Berger, C., Gaume, X., & Bouvet, P. (2015) · Biochimie · doi:10.1016/j.biochi.2015.03.023 · Cited by 273
p63 and p73 in human cancer: defining the network
DeYoung, M. P., & Ellisen, L. W. (2007) · Oncogene · doi:10.1038/sj.onc.1210337 · Cited by 261
T Antigens of Simian Virus 40: Molecular Chaperones for Viral Replication and Tumorigenesis
Sullivan, C. S., & Pipas, J. M. (2002) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.66.2.179-202.2002 · Cited by 258
Well-differentiated and dedifferentiated liposarcomas
Coindre, J., Pédeutour, F., & Aurias, A. (2009) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-009-0815-x · Cited by 254
Structural conservation of druggable hot spots in protein–protein interfaces
Kozakov, D., Hall, D. R., Chuang, G., Cencic, R., Brenke, R., Grove, L. E., Beglov, D., Pelletier, J., Whitty, A., & Vajda, S. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101835108 · Cited by 245
Modulation of Protein–Protein Interactions for the Development of Novel Therapeutics
Πέττα, Ι., Lievens, S., Libert, C., Tavernier, J. H., & Bosscher, K. D. (2015) · Molecular Therapy · doi:10.1038/mt.2015.214 · Cited by 248
The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma
Slack, A., Chen, Z., Tonelli, R., Pulè, M. A., Hunt, L., Pession, A., & Shohet, J. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405495102 · Cited by 239
Ubiquitination and Degradation of Mutant p53
Lukashchuk, N., & Vousden, K. H. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00050-07 · Cited by 223
Discovery of 4-((3′ R ,4′ S ,5′ R )-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development
Aguilar, A., Lu, J., Liu, L., Du, D., Bernard, D., McEachern, D., Przybranowski, S., Li, X., Luo, R., Wen, B., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01665 · Cited by 211
Phosphorylation by Casein Kinase I Promotes the Turnover of the Mdm2 Oncoprotein via the SCFβ-TRCP Ubiquitin Ligase
Inuzuka, H., Tseng, A., Gao, D., Zhai, B., Zhang, Q. H., Shaik, S., Wan, L., Cambronne, X. A., Mock, C. S., Yin, H., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.015 · Cited by 205
Targeting the p53–MDM2 interaction to treat cancer
Klein, C., & Vassilev, L. T. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602164 · Cited by 204
Tyrosine phosphorylation of Mdm2 by c‐Abl: implications for p53 regulation
Goldberg, Z., Sionov, R. V., Berger, M., Zwang, Y., Perets, R., Etten, R. A. V., Oren, M., Taya, Y., & Haupt, Y. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf384 · Cited by 200
Alternative and aberrant splicing of MDM2 mRNA in human cancer
Bartel, F., Taubert, H. W., & Harris, L. C. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00091-0 · Cited by 196
Analyzing the G2/M Checkpoint
Stark, G. R., & Taylor, W. R. (2004) · Humana Press eBooks · doi:10.1385/1-59259-788-2:051 · Cited by 203
MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins
Kobet, E., Zeng, X., Zhu, Y., Keller, D., & Lu, H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.23.12547 · Cited by 193
mdmx is a negative regulator of p53 activity in vivo.
Finch, R. A., Donoviel, D. B., Potter, D., Shi, M., Fan, A., Freed, D. D., Wang, C.-Y., Zambrowicz, B., Ramírez‐Solis, R., Sands, A., et al. (2002) · PubMed · Cited by 192
Molecular mechanisms of cerebral ischemia-induced neuronal death
Hou, S., & MacManus, J. P. (2002) · International review of cytology · doi:10.1016/s0074-7696(02)21011-6 · Cited by 184
Bax Loss Impairs Myc-Induced Apoptosis and Circumvents the Selection of p53 Mutations during Myc-Mediated Lymphomagenesis
Eischen, C. M., Roussel, M. F., Korsmeyer, S. J., & Cleveland, J. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.22.7653-7662.2001 · Cited by 186
β-Peptides as inhibitors of protein–protein interactions
Kritzer, J. A., Stephens, O. M., Guarracino, D. A., Reznik, S. K., & Schepartz, A. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.09.009 · Cited by 187
Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma
Stühmer, T., Chatterjee, M., Hildebrandt, M., Herrmann, P., Gollasch, H., Gerecke, C., Theurich, S., Cigliano, L., Manz, R. A., Daniel, P. T., et al. (2005) · Blood · doi:10.1182/blood-2005-04-1489 · Cited by 180
Implications of Oxidative Stress and Cell Membrane Lipid Peroxidation in Human Cancer (Spain)
Cejas, P., Casado, E., Belda-Iniesta, C., de Castro, J., Espinosa, E., Redondo, A., Sereno, M., García‐Cabezas, M. Á., Vara, J. Á. F., Domínguez-Cáceres, A., et al. (2004) · Cancer Causes & Control · doi:10.1023/b:caco.0000036189.61607.52 · Cited by 179
Stress-Dependent Nucleolin Mobilization Mediated by p53-Nucleolin Complex Formation
Daniely, Y., Dimitrova, D. D., & Borowiec, J. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.16.6014-6022.2002 · Cited by 174
ATM-Mediated Phosphorylations Inhibit Mdmx/Mdm2 Stabilization by HAUSP in Favor of p53 Activation
Meulmeester, E., Pereg, Y., Shiloh, Y., & Jochemsen, A. G. (2005) · Cell Cycle · doi:10.4161/cc.4.9.1981 · Cited by 173
Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment
Gupta, A., Shah, K., Oza, M. J., & Behl, T. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.155 · Cited by 166
The ubiquitin–proteasome system in cardiovascular diseases—a hypothesis extended
Herrmann, S. M. (2003) · Cardiovascular Research · doi:10.1016/j.cardiores.2003.09.033 · Cited by 163
Molecular knots in biology and chemistry
Lim, N. C. H., & Jackson, S. (2015) · Journal of Physics Condensed Matter · doi:10.1088/0953-8984/27/35/354101 · Cited by 162
Sp1 Plays a Critical Role in the Transcriptional Activation of the Human Cyclin-dependent Kinase Inhibitor p21 Gene by the p53 Tumor Suppressor Protein
Koutsodontis, G., Tentes, I. K., Papakosta, P., Moustakas, A., & Kardassis, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104130200 · Cited by 159
Regulating the Regulators: Control of Protein Ubiquitination and Ubiquitin-like Modifications by Extracellular Stimuli
Gao, M., & Karin, M. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.08.017 · Cited by 163
Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma
Maerken, T. V., Speleman, F., Vermeulen, J., Lambertz, I., Clercq, S. D., Smet, E. D., Yigit, N., Coppens, V., Philippé, J., Paepe, A. D., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0792 · Cited by 154
Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation.
Yang, H. S., Filipovic, Z., Brown, D. A., Breit, S. N., & Vassilev, L. T. (2003) · PubMed · Cited by 157
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development
Xiong, S., Van Pelt, C. S., Elizondo-Fraire, A. C., Liu, G., & Lozano, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508500103 · Cited by 155
Does p53 affect organismal aging?
Donehower, L. A. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10104 · Cited by 155
Probing the Structural Requirements of Peptoids That Inhibit HDM2−p53 Interactions
Hara, T. J., Durell, S. R., Myers, M. C., & Appella, D. H. (2006) · Journal of the American Chemical Society · doi:10.1021/ja056344c · Cited by 161
Breaking Bad: How Viruses Subvert the Cell Cycle
Fan, Y., Sanyal, S., & Bruzzone, R. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00396 · Cited by 150
Phosphorylation of Human p53 at Serine 46 Determines Promoter Selection and whether Apoptosis Is Attenuated or Amplified
Mayo, L. D., Seo, Y. R., Jackson, M. W., Smith, M. L., Guzman, J. R., Korgaonkar, C. K., & Donner, D. B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503026200 · Cited by 149
Untitled work
(2003) · PubMed · Cited by 147
DNA Double-Strand Breaks
Bross, L., Muramatsu, M., Kinoshita, K., Honjo, T., & Jacobs, H. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011749 · Cited by 145
Hypophosphorylation of Mdm2 Augments p53 Stability
Blattner, C., Hay, T., Meek, D. W., & Lane, D. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.17.6170-6182.2002 · Cited by 144
Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2
de Graaf, P., Little, N. A., Ramos, Y. F. M., Meulmeester, E., Letteboer, S. J. F., & Jochemsen, A. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213034200 · Cited by 143
Massively regulated genes: the example of TP53
Hollstein, M. C., & Hainaut, P. L. (2009) · The Journal of Pathology · doi:10.1002/path.2637 · Cited by 149
Structure of Free MDM2 N-terminal Domain Reveals Conformational Adjustments that Accompany p53-binding
Uhrı́nová, S., Uhrı́n, D., Powers, H., Watt, K., Zheleva, D. I., Fischer, P. M., McInnes, C., & Barlow, P. N. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.05.010 · Cited by 142
The p53 protein family and radiation sensitivity: Yes or no?
Cuddihy, A. R., & Bristow, R. G. (2004) · Cancer and Metastasis Reviews · doi:10.1023/b:canc.0000031764.81141.e4 · Cited by 137
Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours
Aleixo, P. B., Hartmann, A., de Menezes, I. C. B., Meurer, R. T., & Oliveira, A. M. (2009) · Journal of Clinical Pathology · doi:10.1136/jcp.2009.070201 · Cited by 135
β-Arrestin 2 Functions as a G-Protein-coupled Receptor-activated Regulator of Oncoprotein Mdm2
Wang, P., Gao, H., Ni, Y., Wang, B., Wu, Y., Ji, L., Qin, L.-H., Ma, L., & Pei, G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210350200 · Cited by 134
Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods
Waters, M. D., Jackson, M. A., & Lea, I. A. (2010) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2010.04.005 · Cited by 134
Dual Role of p53 in Innate Antiviral Immunity
Rivas, C., Aaronson, S. A., & Muñoz‐Fontela, C. (2010) · Viruses · doi:10.3390/v2010298 · Cited by 133
Germline mutation of ARF in a melanoma kindred
Hewitt, C. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.11.1273 · Cited by 132
Functional analysis and intracellular localization of p53 modified by SUMO-1
Kwek, S. S., Derry, J. J., Tyner, A. L., Shen, Z., & Gudkov, A. V. (2001) · Oncogene · doi:10.1038/sj.onc.1204362 · Cited by 131
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours
de Jonge, M. J. A., de Weger, V. A., Dickson, M. A., Langenberg, M. H. G., Cesne, A. L., Wagner, A. J., Hsu, K., Zheng, W., Macé, S., Tuffal, G., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.005 · Cited by 130
Mdm2 haplo‐insufficiency profoundly inhibits Myc‐induced lymphomagenesis
Alt, J. R., Greiner, T. C., Cleveland, J. L., & Eischen, C. M. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg133 · Cited by 129
DNA Damage-Induced Phosphorylation of MdmX at Serine 367 Activates p53 by Targeting MdmX for Mdm2-Dependent Degradation
Okamoto, K., Kashima, K., Pereg, Y., Ishida, M., Yamazaki, S., Nota, A., Teunisse, A., Migliorini, D., Kitabayashi, I., Marine, J.-C., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9608-9620.2005 · Cited by 129
Inhibiting S100B Restores p53 Levels in Primary Malignant Melanoma Cancer Cells
Lin, J., Yang, Q., Yan, Z., Markowitz, J., Wilder, P. T., Carrier, F., & Weber, D. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405419200 · Cited by 128
Dysregulation of cellular signaling by HER2 in breast cancer
Zhou, B. P. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.006 · Cited by 127
Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways.
Zhao, L., Samuels, T. L., Winckler, S., Korgaonkar, C. K., Tompkins, V. S., Horne, M. C., & Quelle, D. E. (2003) · PubMed · Cited by 126
p53 induces the expression of its antagonist p73ΔN, establishing an autoregulatory feedback loop
Kartasheva, N. N., Contente, A., Lenz-Stöppler, C., Roth, J. C., & Dobbelstein, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205584 · Cited by 127
Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention
Saha, A., Kaul, R., Murakami, M., & Robertson, E. S. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.10.13923 · Cited by 123
Histone methylation modifiers in cellular signaling pathways
Alam, H., Gu, B., & Lee, M. G. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2023-y · Cited by 124
Structural Biology of the Tumor Suppressor p53 and Cancer‐Associated Mutants
Joerger, A. C., & Fersht, A. R. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(06)97001-8 · Cited by 131
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges
Tundo, G. R., Sbardella, D., Santoro, A. M., Coletta, A., Oddone, F., Grasso, G., Milardi, D., Lacal, P. M., Marini, S., Purrello, R., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107579 · Cited by 120

Authors: Momand, J., Wu, H.-H., & Dasgupta, G.
Affiliations: California State University Los Angeles (US)
Corresponding author: Momand, Jamil
ORCID: Momand, Jamil
Wu, Hsiao-Huei
Venue: Gene
Publisher: Elsevier BV
Published: 2000-01
Volume: 242
Issue: 1-2
Pages: 15-29
ISSN: 0378-1119 (ISSN-L)
DOI: 10.1016/s0378-1119(99)00487-4
OpenAlex: W1973821009
Cited by: 641
References: 144
Citations by year: 2026: 6 · 2025: 11 · 2024: 17 · 2023: 19 · 2022: 24 · 2021: 10 · 2020: 17 · 2019: 16 · 2018: 22 · 2017: 14 · 2016: 17 · 2015: 31 · 2014: 21 · 2013: 21 · 2012: 24
FWCI: 4.03
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Gene (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords: MDM2, p53, tumor suppressor regulation, MDMX, conserved domains, p53 ubiquitination, proteasomal degradation, cell cycle arrest, apoptosis, oncogenes, cancer therapy
MeSH terms: Amino Acid Sequence, Animals, Gene Expression Regulation, Humans, Models, Biological, Molecular Sequence Data, Nuclear Proteins, Proto-Oncogene Proteins, Genes, Tumor Suppressor, Tumor Suppressor Protein p53, Sequence Homology, Amino Acid, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MDM2 — master regulator of the p53 tumor suppressor protein

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks